Fleming, Pannell, and Cross 3 reported that the average death rate from RSV is 6.7 per 100,000 population. Infants with congenital cardiac defects are at greater risk because changes associated with congestive heart failure and cardiac defects limit the ability to compensate during viral bronchiolitis, which in turn increases morbidity and mortality associated with this viral illness 4, 5 . The infection can cause serious illness, prolonged hospitalization, and increased post-operative complications after surgical repair for children with congenital heart malformations 6 ' 7 ' 8 . There may also be long term sequelae, proven by a number of studies linking the infection with increased risk of subsequent development of reactive airway disease 9,10 , 11 compromising the ability of children with congenital heart disease to return to baseline.
Palivizumab (Synagis; Medlmmune, USA) is an IgG humanized monoclonal antibody; and is the first monoclonal antibody successfully developed to combat an infectious disease in humans 1, 12, 13 , first licensed in 1998 by the United States Food and Drug Administration (USFDA). It is used for prevention of serious infection caused by respiratory syncytial virus and is recommended for infants and children at high risk, including patients with hemodynamically significant cardiac disease (both cyanotic and acyanotic lesions). Palivizumab is administered intramuscularly in five monthly doses during the viral season (i.e. November through March) to maintain sufficient serum levels to provide protection against RSV infection 2, 14, 15 .
The effectiveness of RSV prophylaxis has been proven by a large randomized, double-blind, placebo-controlled trial con-ducted between 1998 through 2002 involving 1,287 infants and children younger than two years of age with congenital heart disease. This trial demonstrated the benefit of RSV prophylaxis (Palivizumab) with a 45% reduction in RSV hospitalization in patients with congenital heart disease, 56% reduction in total days of RSV hospitalization, and 73% reduction in total RSV hospital days with increased supplemental oxygen 16 .
The recommendation for RSV prophylaxis in infants and young children with hemodynamically significant congenital heart disease is fairly recent and many clarifications are needed. In 2003 new recommendations were published by the AAP suggesting that children of two years of age or younger with hemodynamically significant lesions would benefit from RSV prophylaxis. Additionally, in 2004 at a European forum for clinical management discussions were held to define the optimal recommendation for RSV prophylaxis in infants and children with congenital heart disease but consensus was not reached on all the issues. Accordingly, the characteristics that identify the infants and children at greatest risk for severe RSV infection and the barriers to administration of RSV prophylaxis remain not well defined 17 . Currently there are approximately 100,000 US infants receiving RSV prophylaxis annually, and until there is an effective RSV vaccine, the RSV prophylaxis with Palivizumab is the best available option for infants and young children at high risk 18 .
The primary purpose of this study was to determine the current pediatric cardiology practice for RSV prophylaxis in infants and children with congenital heart disease and to assess the knowledge and experience of the current recommendations of the AAP for RSV prophylaxis in infants and children with congenital heart disease with the goal of helping to improve the current practice.
Material and Methodology:
Before commencing data collection the survey instrument was pilot-tested to identify any errors and to predict any possible problems. After study approval by Stanford University Institutional Review Board (IRB) an introductory letter was mailed in February 2007 to identify research objectives and to provide website survey access information to all participants in private and academic pediatric cardiology institutions in the United States. An up-to-date list of the target population was obtained from the American Medical Association (AMA) provided by Medical Marketing Services (MMS) which includes 1,399 pediatric cardiologists at different practices in the US.
An anonymous self-reported survey questionnaire was published using the standard School of Medicine web template ''Surveyor" which is an HIPAA (Health Insurance Portability and Accountability Act) compliant online survey fully supported by the Information Resources and Technology Department (IRT) at Stanford University. Individual survey results Were stored in a password-protected Excel spreadsheet. All responses were submitted using secure http (https).
The questionnaire consisted of 53 questions organized into four sections and was designed for completion in approximately 10 minutes. Section one addressed current practice for RSV prophylaxis in patients with congenital heart disease, section two contained questions that focused on recommendations for RSV prophylaxis and section three contained questions to identify the participant's point of view regarding RSV prophylaxis. Section four focused on demographic information. Responses Were made using "Yes" or "No" answers. An informational letter was included with the survey instrument explaining the purpose of the study; anticipated time needed to complete the questionnaire, and instructions for questionnaire submission.
Data analysis and results:
One thousand two hundred and ninety-nine introductory letters were mailed and 81 (6.2%) pediatric cardiologist responded after two mailing, resulting in a 10.5% error rate at the 95% confidence interval. Descriptive statistic is used to analyze the data received. Of the 81 replies received; 42 (52%) Were from academic practice, 24 (30%) from private practice, 13 (16%) from mixed private and academic practice, and two (2%) from Military-based practice. Of these 81 participants, 53 (65%) were male and 28 (35%) female. Thirty-two of the study participants (40%) were in medium size practice (5-10 cardiologists), 26 (32%) from small practices (1-4 cardiologists) and the remaining 23 (28%) from large practices (>10 cardiologists). Detailed demographic information is given in Table 7 .
Most replies were from the West region (n27-33%), 16 (20%) and 17 (21%) from Mid-East and South-East respectively, 13 (16%) were from the North-East. The least number of responses was received from the south-west region (n 5-6%). Three responders did not indicate their region.
Section 1: RSV Practice
All study respondents recommended administration of RSV prophylaxis during RSV season for patients who qualify for the vaccine. Although 66 (81 %) of the replies indicated that they do discuss the preventive measures for RSV infection with parents (i.e. hand wash, avoid crowd areas, etc.), 15 respondent (19%) do not discuss these preventive measures. In comparison with 54 (67%) of the replies, 26 (32%) did not have any guideline or protocol for administration of RSV prophylaxis. The majority of study participants (n73-90%) did not send to parents any written information that describes the risks of RSV infection and benefits of RSV prophylaxis. While 57 (70%) of respondents indicated that they are not routinely screening patients for RSV prior to undergoing surgical procedure using cardiopulmonary bypass; 74 (91%) did screen for RSV infections if the patients presented with respiratory symptoms. Only 43 replies (53%) considered using an additional RSV prophylactic dose following cardiopulmonary bypass surgery. Overall; 36 (44%) respondents considered RSV prophylaxis in patients older than two years of age if they had significant cardiac conditions, 45 (56%) did not recommend RSV prophylaxis in that case. Additional details are illustrated in the table 2.
Section 2: RSV Recommendations
Of 81 replies only 13 (16%) will not continue to administer RSV prophylaxis to patients who reach their second birthday during the RSV season, while 67 (83%) will continue RSV prophylaxis administration, and one didn't respond to this question.
The participants were split between 46 (57%) who will stop administering RSV prophylaxis if the patient has under gone corrective cardiac surgery and did not require any medication and 35 (43%) who will continue to administer the RSV prophylaxis in that situation. Table 3 lists particular medical problems for which pediatric cardiologists consider RSV prophylaxis in children less than two years of age.
Section 3: Point of View
While 51 (63%) of 81 replies received found the criteria for administration RSV prophylaxis recommended by the AAP to clear and well defined; 29 (36%) did not find it clear. Of the 63%, 20% indicated that they had difficulty in deciding about RSV prophylaxis in some cases. Fifty-four (67%) indicated that there was no problem in decision making. The majority of replies (n71-88%) indicated that it is the cardiologist's responsibility to determine the patients who qualify for RSV prophylaxis. In comparison with 60 (74%) of participants, 19 (23%) find that the AAP is not responsible for providing annual update in RSV infection and prophylaxis to the clinician.
Discussion:
Our study found that most pediatric cardiologists were aware of RSV prophylaxis recommendations in infants and children with congenital heart disease based on the current recommendations and guidelines of the AAP. This survey also QATAR MEDICAL JOURNAL | VOL. 18 / NO. 1 / MAY 2009 highlighted areas of conflict in how to deliver the care of RSV prophylaxis to children with congenital heart disease who will mostly benefit from RSV prophylaxis.
Following a four-year multi-center randomized doubleblind, placebo-controlled trial new recommendations were published by AAP to help physician identify appropriate candidates for RSV prophylaxis. These new recommendation first emphasize the importance of prevention, rather than recommendations for RSV prophylaxis, this can be achieved by educating parents, families and care-givers of children at high risk about the preventive measures that can be taken to avoid infectionl7. While most (100%) replies recommend administration of RSV prophylaxis during the RSV season for patients who qualify for the vaccine, and 81 % replies discussed the preventive measures, there was still 19% of participants who indicated that they recommend RSV prophylaxis to high risk patients but also indicated that they did not include preventive measures as part of the discussion. Hence it should be stressed that a major aspect in the recommendation for RSV prophylaxis is the prevention of RSV infection rather than prophylaxis.
Although the current recommendations for RSV prophylaxis by the AAP do not include structured guideline for how to deliver the care, and a high proportion (>80%) of the respondents believed that patients receive RSV prophylaxis somewhere else other than their practice, more than half of the respondents seemed to have well organized practices as they indicated the presence of guidelines, receiving information about update in current recommendations and when to start RSV prophylaxis, assigned qualified individuals responsible for evaluating and following the patients who qualified for RSV prophylaxis and finally communicating with caregivers and facilities where patients receive RSV prophylaxis.
The AAP agreed that most children with congenital heart disease who would benefit from RSV prophylaxis are younger than two years of age. The findings of the survey suggest that about half of the pediatric cardiologists (44%) would consider RSV prophylaxis beyond two years of age in certain children with significant cardiac conditions, and about three-quarters (73%) believed that there are children with significant cardiac conditions who are above two years of age and who should be included in the RSV prophylaxis recommendations.
The current recommendation for RSV prophylaxis include those under two years of age with increased pulmonary blood flow requiring medications, cyanotic congenital heart disease, pulmonary venous congestions, moderate to severe pulmonary hypertension or long-term pulmonary complications, unoperated or partially corrected complex congenital heart disease and hemodynamically significant cardiomyopathy that caused cyanosis or required medications 17. Comparing these recommendations with cardiac conditions mentioned in this survey; most of the participants, (c. 100%) seemed to be clear about some of these recommendations that are well defined by AAP. Study results also highlight the conflicts in certain conditions of congenital heart disease that may qualify for RSV prophylaxis but are not clearly defined by AAP. For example; while agreement reached (99%) that children with congenital heart failure on two or more cardiac condition are qualified for RSV prophylaxis, 80% would considered in children with congenital heart failure who is only on one medication such as lasix, also (99%) of participants would recommend RSV prophylaxis in patient with moderate to severe pulmonary hypertension while 76% would consider it regardless of the degree of pulmonary hypertension.
It was found that the serum concentration level of Palivizumab (the only currently used antibodies for RSV prophylaxis) may fall below protective level (>50%) following cardiopulmonary bypass 16, therefore it was proposed that RSV prophylaxis should be given at the earliest possible once the child is stablel7. The responses received reflects the lack of familiarity with this recommendation, while 53% will consider additional RSV prophylaxis dose after cardio-pulmonary bypass, 38% do not considered it in this case. The reason that 9% did not respond to this part of the questionnaire; could be partly explained that some of the cardiologists are not directly involved with the patients following immediate post operative course.
To protect other children at highest risk for RSV infection who are resident in hospital, The European Forum for Clinical Managements which includes 15 pediatric cardiologist from 8 countries including the United State also includes children with congenital heart disease who are admitted for surgical or interventional procedures during RSV seasonll. Conflicts regarding this issue reached about 50% in the responses received in this survey. Furthermore, there are different responses in the replies received about specific conditions in which pediatric cardiologist may recommend the RSV prophylaxis which is not considered as standard indication by the AAP; such as children with Heterotaxy and children with insignificant cardiac condition who previously required ventilatory support for RSV infection. Explanation of this conflict might depend on many factors; one explanation may be that some of the decision making regarding RSV prophylaxis administration depend on the incidence of the disease in certain region.
RSV prophylaxis should also be considered in patients with unstable cardiac or pulmonary status in whom cardiac transplant was planned, those who had heart transplantation within 30 days and those with recent rejection. While more than 15% didn't respond to this part of the survey indicating that they are not participating in the care of heart transplant patients, the results showed that more than 30% of the pediatric cardiologists did not have this information.
The response rate for this survey is less than optimal, however all the methods to increase the response rate were considered. One of the issue is that; we were not exactly sure how many pediatric cardiologists in the AMA list provided by MMS are still in practice, further more, the actual number of the pediatric cardiologists who received the introductory letter through the mail are also unknown. Perhaps this also fairly typical when surveying health professional; doctors in particular. Though the results from this survey may be different from actual practice; this questionnaire was successful in providing information and determines the diversity between pediatric cardiologists in certain cardiac conditions where RS V prophylaxis should be considered.
A common concern in survey questionnaire is the implication of the survey sample on external validity, and therefore; as in most survey questionnaire, this study has a number of limitations. First, and one of the most important limitations is that it is a self-report survey, and therefore it relies on the answers provided and not on direct observations. The second, which is a factor in personal questionnaire surveys, is that beliefs and thoughts might influence the interpretation of the questions delivered, and therefore the results. Third, this study focuses on Cardiologists' input on RSV prophylaxis in infants and children with congenital heart disease, and does not include other care providers and other conditions that involve RSV prophylaxis administration. Fourth and finally, the research team develops the survey instrument, and hence there is no preexisting data on the reliability and validity of tjie results. Until there is system available to evaluate such practice this self reported survey will remain the most effective evaluation of the current practice and awareness of AAP recommendations for RSV prophylaxis among pediatric cardiologists.
In conclusion, this survey determined that pediatric cardiologists are aware of RSV prophylaxis recommendations in infants and children with congenital heart disease based on current recommendations and guidelines of the AAP. There are still issues that require attention, specifically, reinforcement of the importance of discussing the primary measures in preventing RSV infection with caregivers, a comprehensive review of conflict situations in which infant and children with congenital heart disease will qualify for RSV prophylaxis administration, and provide them with annual information/update in RSV infection and prophylaxis which assists in delivering the care in more practical and cost-effective way. 
